JPWO2014065402A1 - 抗ヒトｃｄ４０モノクローナル抗体及びその利用 - Google Patents

抗ヒトｃｄ４０モノクローナル抗体及びその利用 Download PDF

Info

Publication number
JPWO2014065402A1
JPWO2014065402A1 JP2014543361A JP2014543361A JPWO2014065402A1 JP WO2014065402 A1 JPWO2014065402 A1 JP WO2014065402A1 JP 2014543361 A JP2014543361 A JP 2014543361A JP 2014543361 A JP2014543361 A JP 2014543361A JP WO2014065402 A1 JPWO2014065402 A1 JP WO2014065402A1
Authority
JP
Japan
Prior art keywords
seq
human
antigen
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014543361A
Other languages
English (en)
Japanese (ja)
Inventor
直樹 細見
直樹 細見
石井　敬介
敬介 石井
克志 甲田
克志 甲田
富美子 野村
富美子 野村
恵子 勝見
恵子 勝見
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perseus Proteomics Inc
Original Assignee
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc filed Critical Perseus Proteomics Inc
Publication of JPWO2014065402A1 publication Critical patent/JPWO2014065402A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
JP2014543361A 2012-10-26 2013-10-25 抗ヒトｃｄ４０モノクローナル抗体及びその利用 Pending JPWO2014065402A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012237148 2012-10-26
JP2012237148 2012-10-26
PCT/JP2013/078971 WO2014065402A1 (fr) 2012-10-26 2013-10-25 Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante

Publications (1)

Publication Number Publication Date
JPWO2014065402A1 true JPWO2014065402A1 (ja) 2016-09-08

Family

ID=50544773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543361A Pending JPWO2014065402A1 (ja) 2012-10-26 2013-10-25 抗ヒトｃｄ４０モノクローナル抗体及びその利用

Country Status (2)

Country Link
JP (1) JPWO2014065402A1 (fr)
WO (1) WO2014065402A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017271601A1 (en) 2016-05-27 2018-12-13 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
AU2018336520A1 (en) * 2017-09-21 2020-03-19 WuXi Biologics Ireland Limited Novel anti-CD19 antibodies
WO2019204756A1 (fr) * 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anticorps anti-cd40 et leurs utilisations
CA3103629A1 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activite immunitaire par modulation de facteurs de signalisation post-cellulaires
KR20210070317A (ko) 2018-09-28 2021-06-14 리브젠 바이오파마 코., 엘티디. 조작된 Fc 도메인을 갖는 항-CD40 결합 분자 및 그의 치료적 용도
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
EP4048701A1 (fr) * 2019-10-23 2022-08-31 Lyvgen Biopharma Holdings Limited Molécules de liaison anti-cd40 et anticorps bispécifiques les comprenant
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CA3164129A1 (fr) 2019-12-20 2021-06-24 Amgen Inc. Constructions d'anticorps multispecifique agoniste de cd40 cible par la mesotheline permettant le traitement de tumeurs solides
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.-C. MALMBORG HAGER ET AL.: "Affinity and Epitope Profiling of Mouse Anti-CD40Monoclonal Antibodies.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 57(6), JPN6013056691, 2003, pages 517 - 524, XP002326343, DOI: doi:10.1046/j.1365-3083.2003.01271.x *
JOSEPH A. FRANCISCO ET AL.: "Agonistic Properties and in Vivo Antitumor Activity of the Anti-CD40 Antibody SGN-14.", CANCER RESEARCH, vol. 60(12), JPN6014001840, 2000, pages 3225 - 3231, XP002302208 *
S. FUNAKOSHI ET AL.: "Inhibition of human B-cell lymphoma growth by CD40 stimulation.", BLOOD, vol. 83(10), JPN6014001839, 1994, pages 2787 - 2794 *

Also Published As

Publication number Publication date
WO2014065402A1 (fr) 2014-05-01

Similar Documents

Publication Publication Date Title
US11136413B2 (en) PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
WO2014065402A1 (fr) Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante
US20230218776A1 (en) Anti-ntb-a antibodies and related compositions and methods
JP6273214B2 (ja) がんを処置するためのインテグリンαｖβ６に対する抗体およびその使用
WO2014065403A1 (fr) Anticorps monoclonal anti-cd40 humain et son utilisation
US20190375841A1 (en) Anti-ntb-a antibodies and related compositions and methods
IL254223B2 (en) CD20 binding compounds and their uses
US11497769B2 (en) Anti-CD19 antibodies
KR20160127825A (ko) 항-mcam 항체 및 관련된 사용 방법
CN113645996A (zh) 抗claudin 18抗体及其使用方法
WO2011040565A1 (fr) Anticorps antipodoplanine et composition pharmaceutique contenant un anticorps antipodoplanine
TW201639890A (zh) 結合至ｆｌｔ３蛋白之抗體藥物結合物（ａｄｃ）
KR20210132664A (ko) 항pd-l1 항체 및 그의 용도
US20230080842A1 (en) Tetravalent symmetric bispecific antibodies
JP2022500004A (ja) 抗ｃｄ４０抗体及びその使用
WO2023143343A1 (fr) Anticorps anti-her2/trop2 et leurs utilisations
JP6847434B2 (ja) 抗ポドプラニン抗体
JP2024507959A (ja) 抗Ｓｉｇｌｅｃ１５抗体およびその使用
WO2017061602A1 (fr) Anticorps apte à se lier spécifiquement à la molécule cd147, et son utilisation
WO2024088346A1 (fr) Anticorps anti-ccr8 et leurs utilisations
CN117881701A (zh) 抗cll-1抗体及其用途
CN117430697A (zh) 抗mct1抗体及其用途
EA044092B1 (ru) Анти-ntb-a антитела и терапевтические композиции, их содержащие

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180206